LDLeonor Dias

Leonor Dias

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leonor Dias has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Marta Carvalho

    Neurology Department, Centro Hospitalar Universitário de São João, 4200-319, Porto, Portugal; Department of Clinical Neurosciences and Mental Health, Porto Medical Faculty (FMUP), 4200-319, Porto, Portugal

    3 shared publications
  • Pedro Castro

    Faculty of Medicine, Department of Neurology, Centro Hospitalar Universitário de São João, University of Porto, Portugal (P.C.).

    3 shared publications
  • Elsa Azevedo

    Rise-Health, Department of Clinical Neurosciences and Mental Health, Faculty of Medicine of University of Porto, Porto, Portugal

    2 shared publications
  • Joana Guimarães

    Neurology Department Centro Hospitalar Universitário de São João Porto Portugal

    2 shared publications
  • Luísa Fonseca

    Faculdade de Medicina da Universidade do Porto Portugal

    2 shared publications
  • Madalena Pinto

    Neurology Department Centro Hospitalar Universitário de São João E.P.E. Porto Portugal

    2 shared publications

Latest Publications

  • Open Access

    Red cell distribution width and outcome in acute ischemic stroke patients

    by Leonor Ribeiro Dias, João Pedro Ramalho Gonçalves, Juliana Patrícia Figueiras Ferreira, Luísa Fonseca, Goreti Moreira, Pedro Miguel Araújo Campos Castro


  • Open Access

    Medical Devices for the Management of Patients with Epilepsy

    by João Carrola Costa, Leonor Dias, Marta Carvalho

    The increasing number of medical devices developed and marketed towards management of patients with epilepsy reflects the growing interest in translating technological advances and knowledge about epilepsy into better healthcare for this population. The objective of this narrative literature review is to analyze the available options of medical devices for detecting, treating, and recording epileptic seizures, and their potential clinical application. The included articles were selected from the PubMed database using the query “(Epilepsy[MeSH Terms]) AND (SUDEP)) AND (Medical Device)) AND (English[Language])”. The detection of epileptic seizures is essential for early intervention and to optimize the therapy for each patient. In outpatient settings, this detection is further challenging due to their unpredictability. Traditionally electroencephalography is the direct detection method used in a hospital environment. Indirect methods, such as electrocardiogram, photoplethysmography, oximeter, electrodermal activity, accelerometer, and electromyography, have shown potential for detecting seizures in the outpatient setting. Several medical devices have been developed based on the mentioned methods, with the aim of providing patients with solutions they can use in their daily lives. Behind-the-ear EEG, wristbands, armbands and bed sensors are some of the designs available. Equipped with different features, these devices can answer the need for early seizure detection and improve patients’ and caregivers’ quality of life. There are also devices available for the treatment of epileptic seizures. Through neuromodulation techniques such as vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation, these devices are presented as solutions for patients with refractory epilepsy not eligible for ressective surgery. Patients with epilepsy have several apps available online for proper recording of seizures. These apps help doctors optimize therapy based on clinical evolution. The wide range of devices available creates the opportunity to personalize the approach to patient’s specific needs. Understanding each device’s characteristics can help clinicians improve management of patients with epilepsy. O número crescente de dispositivos médicos desenvolvidos e comercializados para melhorar a gestão de doentes com epilepsia reflete o crescente interesse em traduzir os avanços tecnológicos e o conhecimento sobre epilepsia numa melhor prestação de cuidados de saúde a esta população. O objetivo desta revisão narrativa da literatura é analisar as opções de dispositivos médicos disponíveis para deteção, tratamento e registo de crises epiléticas e a sua possível aplicação clínica. Os artigos incluídos foram selecionados através da base de dados PubMed, utilizando a query “(Epilepsy[MeSH Terms]) AND (SUDEP)) AND (Medical Device)) AND (English[Language])”. A deteção de crises epiléticas é essencial para a intervenção precoce e para otimizar a terapêutica de cada doente. No ambulatório, essa deteção é um desafio devido à sua imprevisibilidade. Tradicionalmente, o eletroencefalograma é o método direto de deteção utilizado em contexto hospitalar. Métodos indiretos de deteção, como eletrocardiograma, fotopletismografia, oxímetro, atividade eletrodérmica, acelerómetro e eletromiografia, mostraram potencial para detetar crises epiléticas em ambulatório. Vários dispositivos médicos foram desenvolvidos com base nos métodos menionados, com o objetivo de fornecer aos doentes soluções que possam usar no seu dia-a-dia. Alguns dos designs disponíveis são o eletroencefalograma com elétrodos retroauriculares, pulseiras, braçadeiras e sensores de pressão na cama. Equipados com diferentes funções, esses dispositivos podem ajudar na deteção precoce de crises epiléticas e melhorar a qualidade de vida de doentes e cuidadores. Existem também dispositivos disponíveis para o tratamento de crises epiléticas. Por meio de técnicas de neuromodulação, como a estimulação do nervo vago, a estimulação cerebral profunda e a neuroestimulação responsiva, esses dispositivos são apresentados como soluções para doentes com epilepsias refratárias não elegíveis para cirurgia ressectiva. Os doentes com epilepsia têm várias aplicações disponíveis online para o registo adequado de crises epiléticas. Essas aplicações ajudam os médicos na otimização da terapêutica com base na evolução clínica. A ampla gama de dispositivos disponíveis cria a oportunidade de personalizar a abordagem às necessidades específicas do doente. O conhecimento das características de cada dispositivo pode ajudar os médicos a melhorar a abordagem dos doentes com epilepsia.

  • Post cerebral venous thrombosis headache – Prevalence, mechanisms and risk factors

    by Leonor Dias, Maria João Pinto, Rúben Maia, Luís Albuquerque, Marta Carvalho


  • “Zebra sign” after a complicated spinal surgery

    by Leonor Dias, José Maria Matos Sousa, João Duarte Silva, Pedro Abreu, Luísa Sampaio

  • Tocilizumab for severe refractory primary central nervous system vasculitis: A center experience

    by Verónica Cabreira, Leonor Dias, Bruno Fernandes, Ana Aires, Joana Guimarães, Pedro Abreu, Elsa Azevedo

    Background Primary Central Nervous System Vasculitis (PCNSV) is responsible for 3%–5% of strokes before age 50. It presents with clinical, radiological, and pathological variability. Optimal management is unknown given the absence of randomized clinical trials. Aims of the study Explore whether tocilizumab, an anti-interleukin-6 monoclonal antibody, is an effective treatment for refractory PCNSV. Methods Patients with PCNSV treated with tocilizumab in a single tertiary center were reviewed. Results Three patients were identified. In two of them, MRI-revealed ischemic lesions. The other presented with a subcortical hemispheric pseudotumoral lesion. Brain biopsy was inconclusive in two patients. Due to a significant number of relapses and clinical deterioration despite other immunosuppressive drugs, tocilizumab was initiated and induced a long remission period up to 44 months. Observed side effects were a fungic infection, neutropenia and thrombocytopenia (both transitory), and a pulmonary embolism in one of the cases. Conclusions Tocilizumab might be a therapeutic option for PCNSV (Class IV evidence), given its efficacy and safety. We propose a novel pathway for diagnosis and therapeutics of PCNSV with the purpose of improving the diagnosis, monitoring, and prognosis of this heterogeneous disorder, setting the framework for future use of tocilizumab in this condition.


  • Risk factors for idiopathic myelitis at admission and predictors for late diagnostic change

    by Leonor Dias, Leonardo Barbosa, Filipa Martins, Luís Braz, Joana Guimarães


  • Open Access

    Acute Inflammation in Cerebrovascular Disease: A Critical Reappraisal with Focus on Human Studies

    by Rafael Azevedo Dias, Leonor Dias, Elsa Azevedo, Pedro Castro

    Recent attention has been focused on the field of inflammatory biomarkers associated with vascular disorders, regarding diagnosis, prognosis, and possible therapeutical targets. In this study, we aimed to perform a comprehensive review of the literature regarding the use of inflammatory biomarkers in stroke patients. We searched studies that evaluated inflammation biomarkers associated with Cerebrovascular Disease (CVD), namely, ischemic Stroke (IS), Intracerebral Hemorrhage (ICH) and Cerebral Venous Thrombosis (CVT). As of today, neutrophil–lymphocyte ratio (NLR) seems the be the most widely studied and accepted biomarker for cerebrovascular disease due to its easy access and availability. Although demonstrated as a prognostic risk factor, in IS, ICH and CVT, its diagnostic role is still under investigation. Several other prognostic factors could be used or even combined together into a diagnostic or prognostic index. Multiple inflammatory biomarkers appear to be involved in IS, ICH, and CVT. Blood inflammatory cells, easily measured and accessible at admission may provide information regarding accurate diagnosis and prognosis. Although not yet a reality, increasing evidence exists to suggest that these may become potential therapeutic targets, likely influencing or mitigating complications of CVD and improving prognosis. Nevertheless, further larger, well-designed randomized clinical trials are still needed to follow up this hypothesis.


  • Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine

    by Leonor Dias, Ricardo Soares-Dos-Reis, João Meira, Diana Ferrão, Pedro Ribeirinho Soares, Ana Pastor, Guilherme Gama, Luísa Fonseca, Vítor Fagundes, Marta Carvalho